Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema.
The Iluvien device is a sustained release implant that delivers fluocinolone acetonide and is indicated to treat diabetic macular edema in people who have been previously given corticosteroids and did not have a clinically significant rise in intraocular pressure.
Get the full story at our sister site, Drug Delivery Business News.
The post Alimera Sciences wins Health Canada nod for diabetic macular edema implant appeared first on MassDevice.